Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
$3.09
-8.0%
$3.11
$1.27
$9.47
$10.79M1.551.28 million shs29,102 shs
Orgenesis Inc. stock logo
ORGS
Orgenesis
$1.51
+13.5%
$1.90
$0.87
$10.80
$7.25M0.478,355 shs3,151 shs
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
$2.55
+6.3%
$2.13
$0.97
$9.79
$11.52M0.912.45 million shs286,333 shs
Palatin Technologies Inc stock logo
PTN
Palatin Technologies
$0.09
-44.6%
$0.11
$0.09
$2.48
$2.45M0.942.28 million shs14.57 million shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
-6.51%+6.19%-2.83%+22.62%+50.73%
Orgenesis Inc. stock logo
ORGS
Orgenesis
+13.53%+2.37%-18.38%-29.77%+150,999,900.00%
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
+4.77%+8.51%-13.85%+152.48%-51.38%
Palatin Technologies Inc stock logo
PTN
Palatin Technologies
0.00%0.00%0.00%+9,409,900.00%+9,409,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Orgenesis Inc. stock logo
ORGS
Orgenesis
N/AN/AN/AN/AN/AN/AN/AN/A
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
2.1746 of 5 stars
3.52.00.00.00.62.50.6
Palatin Technologies Inc stock logo
PTN
Palatin Technologies
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
0.00
N/AN/AN/A
Orgenesis Inc. stock logo
ORGS
Orgenesis
0.00
N/AN/AN/A
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
3.00
Buy$14.00449.02% Upside
Palatin Technologies Inc stock logo
PTN
Palatin Technologies
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest PTN, CYCN, PHIO, and ORGS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/25/2025
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$14.00
6/5/2025
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$14.00
4/8/2025
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00 ➝ $4.00
(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
$2M4.96N/AN/A$3.27 per share0.94
Orgenesis Inc. stock logo
ORGS
Orgenesis
$662K10.95N/AN/A($6.58) per share-0.23
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
N/AN/AN/AN/A$0.69 per shareN/A
Palatin Technologies Inc stock logo
PTN
Palatin Technologies
$350K6.99N/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
-$3.06M-$1.16N/AN/AN/A-34.02%-30.68%8/6/2025 (Estimated)
Orgenesis Inc. stock logo
ORGS
Orgenesis
-$55.36MN/A0.00N/A-3,827.81%N/A-130.18%8/6/2025 (Estimated)
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
-$7.15M-$6.42N/A0.68N/AN/A-105.65%-89.19%8/13/2025 (Estimated)
Palatin Technologies Inc stock logo
PTN
Palatin Technologies
N/A-$1.55N/AN/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
N/AN/AN/AN/AN/A
Orgenesis Inc. stock logo
ORGS
Orgenesis
N/AN/AN/AN/AN/A
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
N/AN/AN/AN/AN/A
Palatin Technologies Inc stock logo
PTN
Palatin Technologies
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
N/A
4.21
4.21
Orgenesis Inc. stock logo
ORGS
Orgenesis
N/A
0.07
0.07
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
N/A
10.58
10.58
Palatin Technologies Inc stock logo
PTN
Palatin Technologies
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
75.62%
Orgenesis Inc. stock logo
ORGS
Orgenesis
22.56%
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
57.31%
Palatin Technologies Inc stock logo
PTN
Palatin Technologies
11.50%

Insider Ownership

CompanyInsider Ownership
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
34.30%
Orgenesis Inc. stock logo
ORGS
Orgenesis
5.66%
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
0.59%
Palatin Technologies Inc stock logo
PTN
Palatin Technologies
7.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
303.21 million2.11 millionNo Data
Orgenesis Inc. stock logo
ORGS
Orgenesis
1504.80 million4.53 millionNo Data
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
104.80 million4.77 millionNot Optionable
Palatin Technologies Inc stock logo
PTN
Palatin Technologies
3026.01 millionN/AN/A

Recent News About These Companies

PL9643 shows promise in dry eye disease treatment

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cyclerion Therapeutics stock logo

Cyclerion Therapeutics NASDAQ:CYCN

$3.09 -0.27 (-8.04%)
As of 07/7/2025 04:00 PM Eastern

Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Orgenesis stock logo

Orgenesis NASDAQ:ORGS

$1.51 +0.18 (+13.53%)
As of 07/7/2025 02:39 PM Eastern

Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.

Phio Pharmaceuticals stock logo

Phio Pharmaceuticals NASDAQ:PHIO

$2.55 +0.15 (+6.25%)
Closing price 07/7/2025 04:00 PM Eastern
Extended Trading
$2.52 -0.03 (-1.02%)
As of 07/7/2025 07:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.

Palatin Technologies stock logo

Palatin Technologies NYSE:PTN

$0.09 -0.08 (-44.65%)
As of 05/7/2025

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.